Bone Marrow and Stem Cell Transplantation at NewYork-Presbyterian HospitalBone marrow and stem cell transplan-tation have become part of the standardof care for patients with hematologicmalignancies and as well as benigndisorders like aplastic anemia. Todaythese therapies are safer and availableto more patients, including older indi-viduals and patients lacking fullymatched donors. NewYork-PresbyterianHospital has been a leader in bonemarrow and stem cell transplantationand is expanding our program withinnovative services based on the latestadvances.

Care is delivered at our two campuses:through the Bone Marrow andPeripheral Blood Stem CellTransplantation Program at WeillCornell Cancer Center, and (starting inMarch 2012) through the Blood andMarrow Transplant Program at theNational Cancer Institute-designatedHerbert Irving Comprehensive CancerCenter at Columbia University.

Types of TransplantationNewYork-Presbyterian Hospital offersthe following types of hematopoietictransplants:• Autologous stem cell transplantation(via bone marrow harvest or periph-eral blood stem cell removal): Thistechnique is commonly used to rebuildthe blood-forming systems of patientswho receive intensive chemotherapy,including select patients with lym-phoma or multiple myeloma.

• Allogeneic bone marrow and stemcell transplantation (includingmatched unrelated donor stem celltransplantation): Transplantation ofbone marrow or stem cells from ahealthy donor is a standard of care for

certain leukemias aswell as non-canceroushematologic disorders.More than half of ourcurrent transplants areallogeneic.

• Cord blood transplan-tation: Umbilical cordblood is a rich sourceof stem cells, whichcan be used to repopu-late the hematopoieticsystem in selectpatients without amatched stem celldonor.

• Reduced intensity("mini") transplanta-tion: This approachuses lower doses ofchemotherapy and little or no radiationtherapy to eradicatecancer cells prior totransplant. This safer alternative is anoption for older patients with chronicleukemia, lymphoma, or multiplemyeloma who may not be able to tol-erate a traditional transplant.

NewYork-Presbyterian/Weill Cornellhas a long history with the NationalMarrow Donor Program and is one ofthe nation's largest centers for collect-ing bone marrow and stem cell dona-tions. We also have an excellent work-ing relationship with organizations suchas Gift of Life and the German BoneMarrow Donor Center (DKMS). The pro-gram is accredited by the Foundationfor the Accreditation of CellularTherapy (FACT).

What We TreatWe treat multiple myeloma, acute andchronic leukemia, Hodgkin and non-Hodgkin lymphoma, solid tumors,severe autoimmune disorders andAIDS, aplastic anemia, sickle cell dis-ease, myelodysplastic syndromes, andthalassemia. The strength and reputa-tion of our hematologic malignancyprograms are exceptional assets forboth campuses.

We also recognize that bone marrowand stem cell transplantation canrequire a lengthy period of treatmentand affect all facets of the lives of ourpatients and their families. Our teamtherefore includes dedicated specialiststo assist with psychosocial support,nutritional support, financial guidance,

ADVANCES IN IMMUNOLOGY ARE IMPROVING TRANSPLANTATIONOUTCOMES. SHOWN HERE: DENDRITIC CELL INTERACTING WITH AT CELL (SOURCE: PAWEL KALINSKI, MD, PHD)

continued on back

FOCUSONCOLOGY in

NewYork-Presbyterian Hospital features two of the country’s top cancer centers: the National Cancer Institute-designatedHerbert Irving Comprehensive Cancer Center of Columbia University Medical Center (one of only three comprehensive NCI-designated cancer centers in New York State) and the Weill Cornell Cancer Center.

and coordination of care. Our hemato-logic oncologists and oncology nursesare also well-versed in the manage-ment of complications such as graft-versus-host disease (GVHD), infections,and graft failure.

Research OpportunitiesOur investigators collaborate with basic science researchers, includingcell and molecular biologists and transplant immunologists, to enhanceour understanding of immunology and apply new discoveries to patientcare. A particular focus at NewYork-Presbyterian/Columbia, in close collaboration with the Columbia Centerfor Translational Immunology (CCTI), isthe development of novel approaches toreduce the risk of allogeneic transplan-tation-induced complications like GVHDwhile preventing disease recurrence,especially in the setting of mismatcheddonor transplants.

Clinical research opportunities forpatients include:• Autologous transplantation: Severalstudies investigate novel medicationsto improve autologous stem cell trans-plantation outcomes for myelomapatients. Working with our lymphomaand myeloma specialists, we also provide autologous transplants for

patients with refractory lymphomawho have otherwise limited options.

• Related and unrelated donor transplantation:We are one of the few centers offering chemotherapyinduction as a “bridge to transplant”for patients with refractory leukemiawith limited options. Our transplantconditioning regimens minimize acuteand chronic GVHD, reducing the lateside effects of transplant.

• Haplo-cord transplantation:NewYork-Presbyterian/Weill Cornell isthe only center in our area evaluatinghaplo-identical cord transplantation, inwhich patients receive stem cells froma partially matched family member in addition to umbilical cord blood.Haplo-cord transplantation is associ-ated with faster engraftment, durableremission, and low GHVD risk. It isbeing assessed primarily in patientswith leukemia, lymphoma, or multiplemyeloma without a matched donor.About half of patients with leukemia inremission and 30 percent of those with

refractory disease obtain prolongedremissions.

• Combination bone marrow/solidorgan transplantation: NewYork-Presbyterian/Columbia will be evalu-ating the combined transplantation ofbone marrow and a solid organ fromthe same donor to treat certainpatients with hematologic disordersand kidney failure. Pioneered by CCTIinvestigators, a combined bone mar-row/kidney transplant can lead tolong-term control of the cancer andacceptance of the kidney without theneed for lifelong immunosuppression(due to the development of immunetolerance) in patients with multiplemyeloma who had developed end-stage renal disease and required anew kidney. Because the new organand the bone marrow come from thesame donor, they "peacefully co-exist." This approach has also beensuccessfully used in patients withoutunderlying malignancies.

525 East 68th StreetNew York, NY 10065

Offering allogeneic andautologous bone marrow and stem cell transplantationfor malignant and benignhematologic disorders

Non-ProfitUS Postage

PAIDNew York, NY

Permit No. 1043

Bone Marrow Program and Stem Cell Transplantation continued from front

For 11 consecutive years, NewYork-Presbyterian Hospital has been listed on the prestigious “Honor Roll” of the U.S.News & World Report “Best Hospitals” survey, and is ranked #1 in the New York metro area. NewYork-Presbyterianhas the most physicians listed in New York Magazine’s “Best Doctors” issue and is recognized by Castle Connolly forhaving more top doctors than any other hospital in the nation.

To refer a patient for bone marrow or stem cell transplantation, please call:NewYork-Presbyterian/Columbia University Medical Center, 212-305-5098NewYork-Presbyterian/Weill Cornell Medical Center, 212-746-2048For more information, visit nyp.org/cancer